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Abstract
Adults with acute lymphoblastic leukemia (ALL) have a poorer prognosis than children due to a 
high risk of relapse. One explanation may be variable adherence to dose-intense chemotherapy. 
However, little is known about risk factors for delays in therapy and their impact on survival.
We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in post-remission 
chemotherapy in adults with newly-diagnosed ALL. Logistic regression was used to identify risk 
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factors for a very long delay (>4 weeks, VLD) in start of intensification therapy. Cox regression 
was used to evaluate the impact of delays on overall and event-free survival (OS, EFS).
We evaluated 1076 Philadelphia chromosome negative (Ph-) patients who completed induction 
chemotherapy, achieved complete remission, and started intensification. Factors independently 
associated with VLD included: duration of hospitalization (Odds Ratio (OR)=1.2, p<0.001) during 
Phase I; thrombocytopenia during Phase I (OR=1.16, p=0.004) or Phase II (OR 1.13, p=0.001); 
chemotherapy dose reductions during induction Phase I (OR=1.72, p<0.014); female sex 
(OR=1.53, p=0.010); Black (OR=3.24, p=0.003) and Asian (OR=2.26, p=0.021) race; and 
increasing age (OR=1.31, p<0.001). In multivariate Cox regression, patients who underwent 
allogeneic stem cell transplant (alloHCT) had significantly worse OS (HR 1.4, p=0.03) and EFS 
(HR 1.4, p=0.02) after experiencing a VLD compared to alloHCT patients who experienced <=4 
weeks delay.
Specific populations (female, older, Black, and Asian patients) were more likely to experience 
delays in chemotherapy, as were those with significant toxicity during induction. Very long delays 
in therapy negatively affected outcomes in patients undergoing allografting.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy treated with 
dose-intense chemotherapy with or without allogeneic hematopoietic stem cell transplant 
(HCT). Despite advances in chemotherapy and supportive care, pediatric patients experience 
better long-term outcomes than adult patients. While 90% of pediatric patients experience 5-
year event-free survival (EFS), only 30-50% of adults achieve this milestone.(1, 2) These 
differences are partially attributable to a higher proportion of adults with biologically high-
risk disease, particularly poor risk cytogenetics such as the Philadelphia (Ph) chromosome.
(3-5)
Variations in administration of therapy between pediatric and adult regimens may also 
account for poorer outcomes among adult ALL patients. Adolescent and young adult 
patients (AYAs), who may be treated by either adult or pediatric oncologists, have been 
studied to better understand the contribution of treatment differences to inferior outcomes 
for adults with ALL. Retrospective studies identify key differences that may contribute to 
improved overall survival (OS) for AYAs on pediatric protocols that include 1) AYAs receive 
higher doses of chemotherapy, especially non-myelosuppressive drugs and 2) have shorter 
intervals between treatment courses.(6-11) Hence, treatment differences, including delays in 
chemotherapy administration, may result in poorer outcomes for adult patients.(12)
While the need for dose-intense chemotherapy in curing hematologic malignancies is well 
described, there is scant literature describing risk factors for and outcomes after 
chemotherapy delays.(13-15) There is a presumption that delaying chemotherapy due to 
toxicity is safer for patients in the short-term, but there are few data that investigate long-
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term consequences such as disease-free and OS.(16, 17) In this study, we investigate risk 
factors for delay in intensification start for adults who underwent therapy on ECOG2993/
UKALLXII, the largest prospective trial for newly diagnosed adult ALL. We also examine 
whether delay is associated with poorer OS and EFS.
METHODS
We performed an analysis of ECOG 2993/MRC UKALLXII, an international clinical trial 
that enrolled 2109 newly diagnosed adult ALL patients age 20-65 between 1993-2006.(18) 
Patients received a 2-phase induction from Day 1-56, followed by a mandatory rest period 
(14 days for MRC, 28 days for ECOG) prior to starting intensification therapy with high-
dose methotrexate (Supp. Figure 1). This trial was registered at http://www.clinicaltrials.gov 
as NCT00002514. Ph- patients who achieved a complete remission (CR) after induction and 
had a documented intensification start date were included in the current analysis. Patients 
who were not in CR, died, or went off protocol prior to intensification were excluded, as 
were those with incomplete documentation for dates of chemotherapy.
The primary outcome was the duration of delay in post-remission intensification therapy. 
The following potential reasons for delay were evaluable in the database: duration of 
neutropenia, thrombocytopenia, hospitalization; patient age; race, cranial-spinal irradiation 
for CNS disease, chemotherapy dose reductions, infection, and time to CR. The secondary 
outcome was to evaluate whether delay in intensification start was associated with decreased 
OS and EFS. OS was defined as time from intensification start to death from any cause. EFS 
was defined as time from intensification start to relapse or death from any cause. Patients 
who were alive (and for EFS, in remission) were censored at date last seen. We chose to use 
intensification start as the start of survival analysis to 1) satisfy the proportional hazard ratio 
assumption and; 2) avoid potential bias when using the date of diagnosis as the survival start 
point, since the most-delayed patients would have increased survival due to longer delay.
Per protocol, patients started intensification on Day+71 (MRC) or Day+85 (ECOG), so 
delay was initially defined as number of days beyond 71 (MRC) or 85 (ECOG) days to 
intensification start. With this definition, however, 1071/1076 (99.5%) patients were 
delayed, with a median time to intensification start of 100 days (range 72-477). Therefore, 
patients were categorized into three delay groups: short delay (SD, <=98 days from start of 
induction to intensification), intermediate delay (ID, 99-112 days) and very long delay 
(VLD, >112 days from start of induction to intensification) for both MRC and ECOG 
patients, allowing both groups 56 days induction and 28 days rest (total 84 days) prior to 
entering a period of delay. Patients with long delay (LD) were those patients with either ID 
or VLD. Hence, LD and VLD corresponded with at least a 2 or 4-week delay beyond 84 
days of induction and rest per protocol for both MRC and ECOG cohorts.
Univariate logistic regression was used to compare LD to SD, and VLD to SD + ID, based 
on demographic factors (age, sex, race) and induction complications (infection, dose 
reductions, CR in >28 days, CNS disease requiring cranial-spinal radiation). The univariate 
analysis was used to identify predictors significantly associated with VLD to include in the 
multivariate analysis. A p-value of ≤ 0.05 in the univariate analysis was considered 
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statistically significant. Multivariate logistic regression was then used to identify predictors 
of VLD. This was done using backward elimination: by removing the weakest non-
significant predictor until all predictors that appear in the reduced model were significant. 
The same variables were included in the multivariate logistic regression model for LD. We 
also explored interactions between the main effect and other significant explanatory 
variables, such as age and sex. Approximately 10% of the patients (105/1076) had some 
missing data for at least one of the continuous variables of interest, and a sensitivity analysis 
using mean imputation was run to assess the effect of missing variables. (19)
Survival curves for OS and EFS were estimated using the Kaplan-Meier method, and 
survival curves for delay groups were compared with the log-rank test. Cox proportional 
hazards regression models were used to estimate OS and EFS hazard ratios (HR) and 95% 
confidence intervals (CI) within subgroups defined by post-remission therapy (allogeneic 
HCT in CR1, autologous SCT, non-transplant therapy). Schoenfeld residuals were used to 
test for the proportional hazard assumption, and there were no violations of the assumption. 
Multivariate Cox regression models were used to adjust for known high-risk disease features 
associated with poorer survival: older age, high-risk WBC at diagnosis, and lineage. 
Interactions between the main effect and post-remission treatment were investigated. Since 
patients allocated to the autologous HCT arm of the study demonstrated inferior outcomes in 
an interim analysis, this arm was excluded from the OS/EFS analysis, but was evaluated for 
the endpoint of risk factors for VLD/LD. Analysis was performed with STATA 12.1 (STATA 
Corporation, College Station, TX).
Institutional review board approval exemption was obtained prior to conducting this study. 
This manuscript was prepared according to the Strengthening the Reporting of 
Observational Studies in Epidemiology recommendations.(20)
RESULTS
Patient Characteristics
There were 1076 patients in our analysis (Supp. Figure 2). Demographics and clinical 
characteristics are outlined in Table I. Missing data rates were <2% for all variables except 
for data reported for evaluation for central nervous system (CNS) disease requiring cranial-
spinal radiation. This information was not documented in 290 cases (27%). Median age was 
28 years (Interquartile range, IQR 20-40). Over 80% of patients achieved CR by day 28 of 
induction.
Risk Factors for VLD
Of the 1076 patients included in this analysis, 270 (25%) had VLD and 577 (54%) had LD. 
In a univariate analysis, female patients (OR=1.72; p<0.001), Black patients (OR=2.70; 
p=0.013), and older patients (evaluated by decade, OR=1.39; p<0.001) were each associated 
with increased risk of experiencing VLD. During induction Phase I, dose reductions and 
infection were associated with VLD (OR=1.83; p=0.002 and OR=1.80; p<0.001, 
respectively). However, during induction Phase II these variables were not significant 
predictors of VLD (dose reduction Phase II OR=1.01; p=0.94; Infection during induction 
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Phase II OR 1.14; p=0.35). In addition, during Phase I and Phase II of induction, duration (in 
weeks) of hospitalization (Phase I OR=1.29; p<0.001; Phase II OR=1.10; p=0.001), 
neutropenia (Phase I OR=1.15; p=0.002; Phase II OR=1.17; p<0.001), and 
thrombocytopenia (Phase I OR=1.27, p<0.001 and Phase II OR=1.19; p<0.001) were 
associated with VLD. Failure to achieve a CR at 4 weeks and cranial-spinal irradiation for 
CNS disease were not significantly associated with VLD (OR=1.01; p=0.98 and OR=0.97; 
p=0.82, respectively). There were no statistically significant interactions for VLD. (Table II)
In the reduced multivariate logistic regression for VLD (Table II, n=1041), three patient 
characteristics were associated with VLD: 1) Sex: women were more likely to have VLD 
compared to men (rates 32% versus 21%, OR 1.53, CI 1.11-2.1, p=0.01); 2) Race: Black 
patients (rates 85% versus 52%, OR 3.24, CI 1.41-7.45, p=0.003) and Asian patients (rates 
64% versus 52%, OR 2.26, CI 1.13-4.52, p=0.021) were more likely to have VLD compared 
to white patients; and 3) increasing age (decades) was associated with VLD (OR 1.31, CI 
1.16-1.49, p<0.001). The other significant predictors in the model were: weeks in the 
hospital Phase I (OR 1.2, CI 1.11-1.31, p<0.001), weeks of thrombocytopenia (Phase I OR 
1.16, CI 1.05-1.28, p=0.004; Phase II OR 1.13, CI 1.05-1.22, p=0.001), and chemotherapy 
dose reductions during Phase I (OR 1.72, CI 1.12-2.64, p=0.014). Multivariate logistic 
regression for LD yielded similar results, except that Asian race and Phase II duration of 
thrombocytopenia were not statistically significant (Table II). A sensitivity analysis was 
done to determine the effect of missing data on multivariate regression and the results were 
similar to the original multivariate with no new predictors of LD or VLD.
Overall Survival
Of the 909 patients included in survival analysis (alloHCT=419, non-transplant=490), 465 
(51.1%) patients died. Median OS from intensification start was 42.6 months (IQR 
12.1-95.5). As delay increased, there was a corresponding decrease in OS (p=0.011, Figure 
1A). The same relationship was seen in both alloHCT and non-transplant settings (alloHCT 
HR=1.19; p=0.045; non-transplant HR=1.19, p=0.021). Using Cox regression, the HR 
associated with VLD compared to ID and SD was significant in both alloHCT and non-
transplant arms (alloHCT HR=1.47, p=0.024; non-transplant HR=1.41, p=0.024), whereas 
there was no significant difference in HR between ID and SD (alloHCT HR=1.03, p=0.86; 
non-transplant HR=1.31, p=0.092), so ID and SD were combined into one cohort that was 
delayed <=4 weeks.
In alloHCT patients, VLD was associated with poorer median OS compared to delay<=4 
weeks (SD+ID), (25.4 versus 47.6 months, p=0.018, Figure 1B). In non-transplant patients, 
a VLD was associated with a non-significant reduction in median OS (38.3 versus 43.2 
months, p=0.08, Figure 1C). VLD was not associated with longer median time from 
intensification start to alloHCT (76 vs. 74 days, p=0.67). Of the 220/419 patients who died 
after alloHCT, VLD (50/220) was associated with shorter time to death after alloHCT (log-
rank p=0.044, Figure 1D). Cause of death was not significantly different between VLD and 
non-VLD patients (relapse in 27% of VLD versus 31% of non-VLD patients; treatment-
related mortality in 73% of VLD versus 69% of non-VLD patients, p=0.55).
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In a multivariate Cox regression that included other high-risk features for decreased OS for 
adults with ALL (B-lineage, elevated WBC, age), for patients who underwent alloHCT, 
VLD remained significantly associated with poorer OS (HR=1.43; CI=1.04-1.97, p=0.027). 
For non-transplant patients, the adjusted HR for VLD was not statistically significant 
(HR=1.12, CI=0.85-1.28, p=0.41) (Table III).
Event Free Survival
Fifty-five percent of patients (500/909) died or relapsed. Median EFS was 36.7 months (IQR 
7.5-90.5). Seven patients had documented relapse prior to intensification start but proceeded 
with intensification (alloHCT=4, non-transplant=3). As delay increased, there was a 
corresponding decrease in EFS (p=0.005, Supp. Figure 3A). The same relationship was seen 
in both alloHCT and non-transplant patients (alloHCT HR=1.19, p=0.038; non-transplant 
HR=1.22, p=0.007). After a VLD, alloHCT patients had poorer EFS than those delayed <=4 
weeks (median 12.8 vs. 39.5 months, p=0.024, Supp. Figure 3B). Patients who received non-
transplant post remission therapy had poorer EFS after VLD, which was marginally 
statistically significant (median 32.4 months vs. 41.0 months, p=0.05, Supp. Figure 3C).
In a multivariate Cox regression, adjusted for age by decade, lineage, and high-risk WBC at 
diagnosis, for alloHCT patients VLD was associated with poorer EFS (HR 1.43; CI 
1.05-1.95, p=0.024). For non-transplant patients, the effect of VLD was not statistically 
significant: p=1.16 (CI 0.88-1.52, p=0.28) (Table III).
DISCUSSION
In the largest prospective trial of adults with ALL, we were able to identify several risk 
factors for chemotherapy delays and to show that these delays are linked to inferior 
outcomes. Specifically, delays in initiation of post-remission intensification occur nearly 
universally and more frequently occur in older, female, Black and Asian patients as well as 
those who experience excess toxicity from initial chemotherapy. For each decade of 
increasing age there was a nearly 40% increase in odds of VLD, suggesting that poorer 
outcomes experienced with increasing age may be due in part to greater incidence of longer 
delays. Although prolonged thrombocytopenia during induction was associated with longer 
delays, neutropenia was not. The trial allowed G-CSF, which may have facilitated marrow 
recovery to the required WBC of 3,000/uL to start intensification. Hence, G-CSF may be 
helpful in preventing delays even if it does not reduce infection rate or mortality.(21) (22) 
While it is unreasonable to suggest that physicians should continue on-schedule therapy for 
patients with active therapy complications such as sepsis or organ failure, our findings 
suggest a thoughtful re-evaluation of the feasibility of induction via two continuous phases 
in the adult population, particularly in older patients, in comparison with AYA protocols.
Black patients had a significantly higher risk of experiencing LD and VLD, and Asians had 
higher risk of VLD. Retrospective and population studies have demonstrated poorer survival 
rates among African-American cancer patients compared to Caucasian patients, despite 
improved 5-year cancer survival rates in all patients.(23) (24) (25) It has been suggested that 
poorer survival rates may not extend to minority patients enrolled in clinical trials, 
potentially reflecting biases in patients who enroll and suggesting that support services 
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offered in a clinical trial setting that may improve therapy adherence.(26) Adult studies do 
not measure whether suboptimal adherence to dose-intense therapy is associated with 
survival outcomes, whereas the pediatric literature demonstrates that poorer adherence to 
maintenance oral 6-mercaptopurine therapy is seen in African-American and Asian pediatric 
patients, and may be associated with relapse.(27) In pediatric ALL there are clear survival 
differences in minority populations, which may be due to genetic predispositions, 
environmental factors, and/or access to care. (28-30) Our study shows that adult minority 
patients also face risks for delays in dose-intense therapy and these risks may partially 
explain poorer survival outcomes observed in population studies. Further analyses are 
needed to better understand these risk factors in adult minorities with ALL.
While there is population and clinical trial evidence that males have poorer survival for 
leukemia, there is little data on disparities in care by sex for adults with leukemia. (18, 31) 
We find that, even after adjusting for older age, females experienced more frequent delays. 
The reason for this is unknown — one could postulate that LD in females may be related to 
childcare planning or family support. It is not known whether patients were married or in a 
marriage-like relationship, which may impact social support at home and influence delay. 
(32)
Our study confirms that longer delays are associated with decreased OS and EFS. This effect 
was particularly robust in the alloHCT population: those who experienced VLD were 40% 
more likely to relapse or die even after adjusting for older age, lineage, and high-risk WBC. 
It is not clear why a >4-week delay (rather than 2-4 weeks) was the critical duration to 
negatively impact survival. VLD may be a quantitative marker for poor patient performance 
status or sensitivity to chemotherapy toxicity. Pharmacokinetic and pharmacogenomic 
studies (with the exception of thiopurine methyltransferase testing in patients with 
myelosuppression on mercaptopurine) are typically not performed in adult ALL patients. 
Unplanned treatment delays may represent a biologic marker of intolerance to cytotoxic 
agents, predicting a worse outcome in high-risk procedures such as alloHCT. While there are 
several risk assessment models for mortality with alloHCT based on medical co-morbidities 
and disease status, delays during induction may also identify patients who are particularly 
intolerant to cytotoxic chemotherapy and may have additional uncaptured risk with alloHCT. 
(33) (34)
Delay could have been a factor in choosing whether to pursue alloHCT, as the registration to 
the alloHCT arm occurred just prior to intensification start. Physicians may have opted for 
alloHCT for delayed patients who were not originally assigned to alloHCT arm, feeling that 
they did not receive optimal dose-intense therapy. The effect of VLD could not be overcome 
despite intensified therapy for these patients. It is important to note that delays in 
intensification start should not be attributable to transplant planning logistics, as the 
registration to the alloHCT arm was made after the delay period, so transplant logistics 
(referral to transplant center, insurance approval) would have occurred after our measured 
delay.
There was a suggestion that VLD may have negatively impacted survival in patients who 
received non-transplant therapy. In particular, after 4 years, there is divergence in survival 
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between VLD and non-VLD patients. Such a late divergence may reflect that delayed 
patients are dying from other causes, or that they may be a sicker population in general.
Although not part of our intended analysis, we also observed significant deviations from 
planned therapy after intensification. Of the 490 non-transplant patients, only 324/490 (66%) 
were documented to start consolidation. 262 of these 324 patients (81%) completed 
consolidation. 196 patients started maintenance therapy, and only 65/490 non-transplant 
therapy patients (26%) are recorded to have completed maintenance. This suggests that 
delays and non-adherence likely extend to continued chemotherapy after remission and that 
the non-transplant patients may not have received optimal therapy on an ongoing basis.
The ECOG2993/UKALLXII trial did not document many details about induction toxicity 
and chemotherapy delays. Data that was not collected include reasons for prolonged 
hospitalization and chemotherapy dose reductions. Interestingly, although intensification 
was clearly delayed based on dates, many of these patients were not identified as “delayed,” 
which is why reasons for delays were also frequently not noted. The trial did not evaluate 
ongoing performance status, co-morbidities, and medical events experienced prior to 
intensification start. We have no information on marital status and financial/employment 
information, insurance status, or other sociodemographic features. Disparities by sex and 
race in our study suggest that social risk factors likely exist. Our survival analysis did not 
incorporate high-risk cytogenetics due to significant missing data. A sub-analysis with data 
on 419 alloHCT patients did demonstrate, however, that VLD was still associated with 
poorer OS and EFS after accounting for MLL rearrangements. Lastly, as our analysis was 
restricted to patients on the ECOG 2993/UKALLXII protocol, it is difficult to quantify risks 
of delays in other ALL treatment regimens, including those administered off protocol.
In conclusion, we observe that in adults with ALL, specific patient populations (older, 
female, Black, Asian, and those experiencing significant chemotherapy toxicity) are at risk 
for experiencing lengthy delays in initiation of post-remission treatment. In an adjusted 
analysis, VLD is associated with poorer OS and EFS; this effect is most pronounced in 
patients who underwent alloHCT. Further studies are needed to identify potentially 
modifiable risk factors, so that interventions may be offered to optimize adherence to these 
intensive chemotherapy regimens, which we expect will contribute to more favorable long-
term outcomes for adults with ALL.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
OS: overall survival; VLD: very long delay; SD: short delay; LD: long delay
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